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Arylamine N-acetyltransferases, NAT1 and NAT2, catalyze the 
detoxification and/or activation of drugs and aromatic amine carcinogens. Single 
nucleotide polymorphisms or SNPs result in different human NAT2 genotypes thus 
dividing the population into rapid, intermediate, and slow acetylators. We 
hypothesize allelic variants of NAT2 genotype will decrease levels of N-acetylation, 
cytotoxicity, oxidative stress, DNA adduct formation, and mutagenesis compared 
to the reference allele NAT2*4. Cryopreserved human hepatocytes expressing 
different NAT2 genotypes and NER-deficient Chinese hamster ovary (CHO) cells 
transfected with human CYP1A2 and human NAT2*4, NAT2*5B or NAT2*7B have 
been used to investigate N-acetylation of different xenobiotics. In vitro and in situ 
N-acetylation products of hydralazine and isoniazid (INH) as drugs and 4-
aminobiphenyl (ABP), β-naphthylamine (BNA), and 4, 4’-methylene bis (2-
chloroaniline) (MOCA) as carcinogens were measured using high performance 
liquid chromatography  (HPLC).   
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Cell viability was measured using alamar blue assay. Our findings showed 
that N-acetylation rates of ABP, BNA and MOCA in rapid acetylators are higher 
than slow acetylators. Also, CHO cells expressing NAT2*4 (rapid acetylator) 
showed higher N-acetylation rates of hydralazine, INH, BNA and MOCA than cells 
expressing slow alleles NAT2*5B or NAT2*7B. N- acetylation rate of hydralazine 
in CHO cells expressing NAT2*5B was insignificantly higher compared to 
NAT2*7B N-acetylation rates of hydralazine. However, For BNA, N- acetylation 
rate in CHO cells expressing NAT2*5B was insignificantly lower compared to 
NAT2*7B suggesting genetic heterogeneity within the slow NAT2 phenotype. 
Treatment of cells with ABP, BNA and MOCA resulted in concentration dependent 
cytotoxicity in human hepatocytes and CHO cells. These data suggest that 
individual susceptibility to side effects or carcinogenicity can be modified by human 
NAT2 genotype. Moreover, NAT2 slow acetylator phenotype is not homogeneous, 
but rather multiple slow acetylator phenotypes exist resulting from different 
mechanisms inferred by various SNPs. Therefore, the investigations of NAT2 
genotype/phenotype relationship could be more precise if heterogeneity within the 
“slow” NAT2 acetylator phenotype is incorporated into future lab-based, pre-
clinical and clinical studies. These results are important for future studies to 
determine the role of NAT2 genotype on the toxic effects of aromatic amines such 
as DNA damage, DNA adducts and mutagenicity.
vii 
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Arylamine N-acetyltransferases (NATs) are xenobiotic metabolizing 
enzymes that play an important role in the metabolism and detoxification of many 
drugs and carcinogens [1]. Two NAT genes (NAT1 and NAT2) have been 
annotated in humans, both are located on chromosome 8 between 170-360Kb at 
8p22 (Figure 1) [2]. NAT1 and NAT2 genes consist of 873 bp with similar structure. 
However, they exhibit different physiological roles and substrate affinities [3]. NAT1 
shows substrate specificity for p-aminobenzoic acid (PABA), while NAT2 shows 
substrate specificity for sulfamethazine [4].  
 
 Figure (1): Schematic representation of NAT genes on human chromosome 




Although NAT2 has restricted tissue expression, NAT1 is expressed in 
almost all tissues of the body. Recent studies have suggested a novel role for 
NAT1 in cancer cell growth, survival, and resistance to chemotherapy [5, 6]. 
Regarding NAT2, it is a typical xenobiotic metabolizing enzyme expressed mainly 
in the small and large intestine and the liver. Also, its mRNA was detected in 
diverse human tissues [7]. 
NAT1 and NAT2 catalyze N-acetylation or O-acetylation of drugs, aromatic 
and heterocyclic amine carcinogens. NAT2 catalyzes N-acetylation of many drugs 
such as sulfamethazine, isoniazid (INH), hydralazine, procainamide and dapsone 
[8]. Also, it catalyzes both N-acetylation (usually deactivation) and O-acetylation 
(usually activation) of aromatic and heterocyclic amine carcinogens such as: 4 
aminobipnenyl (ABP), β-naphthylamine (BNA) and 4,4’-methylenebis (2-
chloroaniline) or (MOCA), which can be found in chemical, dye and rubber 
industries as well as in hair dyes, paints, and cigarette smoke [9].  
Both human NATs are polymorphic enzymes (about 28 NAT1 and 108 
NAT2 alleles) http://nat.mbg.duth.gr/ resulting in three acetylator phenotypes, 
rapid, intermediate, and slow acetylators [10, 11]. NAT2 genetic polymorphism was 
first noticed when isoniazid was used as anti-tuberculosis drug. Patients with less 




There are many known polymorphisms in the NAT2 gene resulting from 
single nucleotide polymorphism or SNPs. These SNPs are associated with 
decreased enzyme activity and variable stability [13-15]. Figure (2) illustrates 





The difference between allelic frequencies in the different populations are 
shown in (Table 1). The reference allele NAT2*4 is associated with the acetylator 
phenotype, although NAT2*12 and NAT2*13 were also identified as rapid 
acetylators in African populations [10, 16]. The remaining alleles, NAT2*5, 
NAT2*6, NAT2*7, and NAT2*14, and their subtypes are typically associated with 
Figure (2): Schematic illustration of NAT2 allelic variants. The reference allele 
(NAT2*4) and the most common allelic variants (NAT2*12A, 5A, 5B, 6A, 7B). 
Adapted from [17]. 
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the slow acetylator phenotype [17]. NAT2*4 makes up 20–25% of alleles in 
Caucasians. The reference allele NAT2*4 is higher among African Americans (36–
41%), Hispanics (41%), Chinese (50%) and Japanese (70%) relative to 
Caucasians [18]. 
NAT2*5 allele is the most common slow genotype among Hispanics (25%), 
Africans (27%), and Caucasian (44%) relative to Chinese (1.9-5.5%) [19, 20]. 
NAT2*6 is evenly distributed across the different ethnic groups (22-28%), while 
Chinese have NAT2*7 (17%) as the common slow allele [21, 22]. NAT2*14 is 
exclusively present in sub-Saharan Africa [23]. 
 
 
 Africans Asians Caucasians Hispanics 
NAT2*4 36-41 % 50-70% 20-25% 41% 
NAT2*5 27% 1.9-5.5% 44% 25% 
NAT2*6 22% 21% 28% 21.9% 
NAT2*7 2% 17% 1.3% 9.2% 
NAT2*12 12-20% 2.5% 4% 4.5% 
NAT2*14 9% 0.0 0.0 0.0 
 




Increased risk for drug toxicity, therapeutic failure or cancer are associated 
with the presence of these different genotypes [24]. For instance, patients who 
inherit the slow NAT2 genotype have an increased risk of developing isoniazid 
induced liver injury relative to those with the rapid NAT2 genotype [25]. Moreover, 
carriers of the slow acetylator genotype are linked with higher blood pressure 
following hydralazine treatment relative to rapid acetylators. However, slow 
acetylators experience greater adverse effects in form of lupus like syndrome 
because of the low acetylation rate [26]. This can be explained by the inhibitory 
effect of hydralazine on the complement system that may contribute to impaired 
clearance of immune complexes and thus to systemic lupus erythematosus [1].  
Regarding cancer susceptibility, slow NAT2 acetylation status has been 
associated with a high risk of developing urinary bladder cancer, since they have 
a decreased capacity to detoxify aromatic amines by N-acetylation [27, 28]. N-
acetylation of aromatic amines such as 4-aminobiphenyl (ABP) is generally 
considered as a detoxification step. It competes with P450-catalyzed N-
hydroxylation followed by O-acetylation of N-hydroxy-amine catalyzed by NAT2 
that generates acetoxy-derivatives that are highly unstable, leading to the 
formation of an arylnitrenium ions that binds to DNA leading to mutagenesis and 
carcinogenesis [29] (Figure 3).  
Therefore, rapid acetylators have faster detoxification of aromatic amines 
so they can be excreted from the body while slow acetylators are more likely to 
metabolic bioactivation via O-acetylation pathway. The later leads to formation of 
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an arylnitrenium ions and DNA adducts then carcinogenesis if DNA is not repaired 
by repair pathway [30]. 
4-aminobiphenyl (ABP), is an environmental and occupational contaminant 
that can cause urinary bladder cancer in humans through inhalation and dermal 
penetration. It is mainly generated through the combustion of fossil fuels and from 
rubber, coal, textile, hair dyes industries [31, 32]. The International Agency for 
Research on Cancer (IARC) has classified ABP as a group I carcinogen [33].  
Despite the cessation of commercial ABP production and use, smokers are 
still exposed to 2–5 ng ABP for each cigarette smoked [34] Also, bladder cancer 
biopsies from smokers have significantly higher levels of 4-ABP–DNA adducts 
than nonsmokers [34]. Moreover, increased levels of ABP hemoglobin adducts 
have also been found in the erythrocytes of smokers. DNA adducts result from 









Although, some of aromatic amines have affinity to be acetylated with NAT1 
and NAT2, human NAT2 has a three to four-fold higher affinity than NAT1 for 
urinary bladder carcinogens such as ABP, BNA and MOCA [10, 35]. This may 
explain how NAT2 genetic polymorphism, regardless of NAT1 acetylator type, may 
Figure (3): Pathways of detoxification and bioactivation of ABP as an 
example of aromatic amines. Adapted from [30]. 
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influence cancer risk among humans exposed to these carcinogens even in low 
doses [36]. 
Both rapid and slow NAT2 acetylator phenotypes have been associated 
with increased cancer in different target organs related to arylamine exposure [37]. 
For instance, many studies have associated increased urinary bladder cancer risk 
with inheritance of the NAT2 slow phenotype, especially, the NAT2*5B genotype. 
Slow acetylators are less likely to detoxify ABP and the procarcinogen is more 
likely to undergo metabolic activation via O-acetylation leading to increased 
formation of arylnitrenium ions and DNA adducts then carcinogenesis, if not 
repaired by DNA repair pathways [38-40]. On the other hand, the risk of colorectal 
cancer from well-done cooked meat, containing higher levels of meat derived 
carcinogens (i.e., heterocyclic aromatic amines or HAAs), was higher among rapid 
acetylators compared to slow acetylators [41-44]. These data suggest the 
association of cancer risk with NAT2 phenotype may be exposure and organ 
specific. 
Moreover, epidemiological studies show the implication of NAT2 genetic 
polymorphism in the development of malignancies involving the breast [22], 
prostate [45], liver [46], and lung [47]. However, except for the smoking-related 
urinary bladder cancer, these studies have been unable to establish a consistent 
association between the acetylator status and human cancers [48].  
Although previous studies have shown aromatic amines such as ABP 
undergo N-acetylation to acetyl metabolites in animals and humans, very little is 
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known regarding whether their metabolism is subjected to the NAT2 genetic 
polymorphism. Also, earlier studies have not provided a clear evidence for the 
association between N‐acetylation and cytotoxicity or genotoxicity of some 
aromatic amines. Therefore, more laboratory-based experiments are needed to 
investigate the role of NAT2 genetic polymorphism in N-acetylation of aromatic 
amines. It is our hypothesis that different NAT2 alleles can decrease N-acetylation 
rates of these aromatic amines and the associated cytotoxicity compared to the 
reference rapid allele NAT2*4. 
In the current study we selected isoniazid, and hydralazine as drugs and 
ABP, BNA, and MOCA as carcinogens to investigate the effect of NAT2 
polymorphism on their N-acetylation rates. 
HYDRALAZINE: 
 Hydralazine is a potent vasodilator widely used to treat hypertension during 
pregnancy as well as heart failure [49]. Recently, it has been shown that 
hydralazine may have an epigenetic role in cancer treatment through its ability to 
cause reversible heritable changes in gene expression without alterations in the 
DNA sequence [50, 51]. Hydralazine acts as a DNA methylation inhibitor by 
reducing the expression of the DNA methyltransferases which are involved in 
aberrant cytosine methylation in mammalian DNA [52, 53]. Clinical trials have 
revealed a protective role of hydralazine, either alone or with combination with 
valproate, in relation to many types of cancer including cancer cervix [54] T-cell 
lymphoma [55].  
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Two pathways have been proposed for hydralazine metabolism in humans. 
First, direct acetylation through NAT2, forming the metabolite 3-methyl-s-triazolo 
(3,4-a)-phthalazine (MTP) leading to detoxification. Second, hydralazine may also 
undergo bioactivation to form N-acetylhydrazinophthalazinone (NAc-HPZ) via an 




Our laboratory revealed N-acetylation of hydralazine in human hepatocytes 
is higher in rapid acetylators compared to intermediate and slow acetylators [57].  
 
Figure (4): Metabolism of hydralazine in humans. (H) hydralazine, 
(MTP) 3-methyl-s-triazolo (3,4-a)-phthalazine, (3-OH-MTP) 






Isoniazid (INH) is one of the current highly effective therapies against 
Mycobacterium tuberculosis. The major pathway for metabolizing INH involves N-
acetylation to acetyl-isoniazid by NAT2 and this is considered as detoxification. 
However, if AcINH is converted to AcHz and hydroxylation via CYP2E1 occurs, 
this will lead to formation of toxic reactive metabolites (Figure 5) [58]. The rate of 
acetylation is constant in every individual but varies according to NAT2 genotype 
[59]. Doll and co-workers mentioned that N-acetylation of INH is genotype-
dependent in human cryopreserved hepatocytes both in vitro and in situ following 










Figure (5): Metabolic pathways of isoniazid in humans. INH, Isoniazid; 





In addition, a recent meta-analysis revealed isoniazid induced hepatitis is 
more likely to occur in patients with NAT2 slow acetylator genotype compared to 
rapid and intermediate acetylators across all social ethnic variations including 
Africans, Asians, Hispanic and Caucasians. This suggests it should be required to 
closely monitor patients with tuberculosis carrying the NAT2 slow acetylator 
genotype is required to detect hepatotoxicity induced by INH-based treatment [61]. 
 
β-NAPHTHYLAMINE (BNA): 
Regarding 2-Naphthylamine or β-naphthylamine (BNA), it was formerly 
used commercially as an intermediate in the manufacturing of dyes, and as an 
antioxidant in the rubber industry. Also, environmental exposure occurs due to 
cigarette smoking. BNA amounts in mainstream and side stream cigarette smoke 
range from 1–22 ng/cigarette and 113.5–171.6 ng/cigarette, respectively [62]. It 
has been classified as a definite human carcinogen for bladder cancer by the 
International Agency for Research on Cancer and can be absorbed through the 
lungs or skin [63].   
BNA undergoes N- and/ or O-acetylation via NATs. O-acetylation leads to 
formation of nitrenium ions that can bind to DNA forming DNA adducts (Figure 6). 
Previous studies have illustrated the association between BNA exposure due to 
smoking or occupation as well as NAT2 slow genotype alleles (NAT2*6A and/or 








Figure (6): Proposed metabolic activation and detoxification pathways 
for the aromatic amine β-naphthylamine [67]. 
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4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
MOCA is used primarily in polyurethane industry. MOCA has been linked to 
hepatomas in mice and rats, lung, and mammary tumors in rats as well as bladder 
cancer in dogs [68-70]. As it is one of the aromatic amines, MOCA undergoes 
detoxification through an N-acetylation process catalyzed by NAT1 and NAT2 
(Figure 7). However, in a previous study done by our lab, MOCA exhibited about 
4-fold higher affinity for recombinant human NAT2 relative to NAT1. Also, N-
acetylation rates of MOCA by human NAT2*5, NAT2*6, NAT2*7, and NAT2*14 
were much lower than the reference NAT2*4 allozyme. [71].  
In another study, industrial workers who were exposed to MOCA and had 
the NAT2 rapid alleles (*4, *12 A, B, C) had less oxidative damage compared to 






Figure (7): N-acetylation of MOCA to form the acetylated product [71]. 
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Since DNA damage and mutagenesis are harmful consequences of both 
environmental exposure and carcinogen metabolism, they are informative 
biomarkers to investigate genetic variation in carcinogen metabolism. One 
important mechanism of DNA damage following exposure to carcinogens is the 
oxidative stress induced by reactive oxygen species (ROS) [73]. These ROS can 
bind to DNA, which may lead to oxidative DNA damage and ultimately many 
pathological conditions such as age dependent cataract, diabetes mellitus, chronic 
hepatitis [74-78] and cancer [79-82].  
ROS are produced by the metabolism of environmental arylamine 
genotoxins such as chemical carcinogens and environmental agents [83]. ROS 
can lead to deleterious and extensive DNA damage including single strand breaks 
and DNA adduct formation. Modified bases such as 8-hydroxy-deoxyguanosine 
(8-OHdG) can be used as a marker to evaluate DNA damage caused by oxidative 
stress [84, 85].  
Many studies showed the relationship between exposure to arylamine 
carcinogens and oxidative DNA damage. A study done previously among MOCA 
exposed workers showed that 8-OHdG concentration of rapid and intermediate 
acetylators was lower than that of the control group [72]. Also, Zhang et al., stated 
that 2-Amino-9H-pyrido[2,3-b] indole (AαC), which is present in high quantities in 




In addition, NO-naphthol, a metabolite of BNA caused oxidative DNA 
damage that includes formation of 8-OHdG [87]. Moreover, reactive oxygen 
species including H2O2 may result in cytotoxicity upon exposure to certain drugs 
such as hydralazine which could explain the associated hepatitis in some patients 
[88]. 
Several studies evaluated the role of aromatic amines in relation to 
mutagenicity. For instance, BNA and MOCA increase mutant formation in bacterial 
strains [89]. Also, our lab reported heterocyclic aromatic amines such as 2-Amino-
9H-pyrido[2,3-b] indole or AαC can induce mutations in a dose-dependent manner. 
These mutations were found to be higher in cells transfected with NAT2*4 than 
cells transfected with NAT2*5B [90]. More recently, Baldauf and coworkers 
reported mutagenesis induced by ABP and 2-aminofluorene (AF) was significantly 
higher in the Chinese hamster ovary (CHO) cells that were stably transfected with 
human CYP1A2/NAT2*4 compared to cells expressing human CYP1A2/NAT2*5B 
[91]. CHO cells lack nucleotide excision repair (NER) and allows the evaluation of 
CYP1A2 with NAT2 role in metabolism in the absence of NAT1. 
Most of the previously mentioned studies have inferred NAT2 phenotype 
from genetic classification of the population into rapid, intermediate, and slow 
acetylators. However, clinical studies suggest different NAT2 alleles lead to 
heterogeneity of the acetylation status within the same phenotype [15]. One study 
showed antituberculosis drug-induced hepatotoxicity risk is particularly high 
among carriers of the NAT2*6/*6 allele. This suggests NAT2*6/*6 carriers 
individuals may constitute a subcategory of “ultra or very slow” acetylators [92]. 
17 
 
Another study done in 504 north American subjects of Caucasian origin 
indicated there were variations in the N-acetylation NAT2 status among slow 
acetylator individuals. NAT2*6/*6 homozygotes show roughly a 30% reduction on 
enzyme activity as compared to NAT2*5/*5 homozygotes although both are 
considered slow acetylators [93]. Nonetheless, the role of these allelic variants in 
metabolism of arylamine carcinogens have yet to be investigated. Previous 
experimental studies investigated the effect of NAT2 polymorphism on arylamine 
carcinogens in rabbit or rat hepatocytes [94, 95]. In the current study, we 
investigated N-acetylation of ABP, BNA and MOCA as arylamine carcinogens in 
cryopreserved human hepatocytes that included rapid, intermediate, and slow 
acetylator genotypes. Human hepatocytes are an important model system to study 
the synergistic effects of CYP1A2 and NATs genes on the metabolism of different 
xenobiotics. 
Also, we investigated the N-acetylation of hydralazine, INH, ABP, BNA and 
MOCA in Chinese hamster ovary (CHO) cells. To compare the effect of NAT2 
allelic variants on the heterogeneity within the same phenotype, UV5-CHO cells 
were stably transfected with human CYP1A2 and either NAT2*4 (as rapid 
acetylator), NAT2*5B (as common slow acetylator in Caucasians) or NAT2*7B (as 
common slow acetylator in Asians). The stable expression of CYP1A2 and NAT2 
can reveal the individual role of NAT2 heterogeneity independent of possible 
confounding by NAT1. In addition, since UV5-CHO cell line lacks nucleotide 
excision repair (NER) due to a mutation in the XPD (ERCC2) gene, it is 
hypersensitive to bulky adduct mutagens [96].  
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Previous studies showed that the gene-gene interaction between different 
xenobiotic metabolizing enzymes particularly NATs an CYP1A2 can determine the 
individual risk to develop cancer. For instance, Cascorbi and coworkers showed 
individuals who carry NAT2*4 and NAT1*10 are at lower risk to develop bladder 
cancer when exposed to carcinogens either by smoking or occupational exposure 
[97].  
Also, a meta-analysis, demonstrated inheritance of NAT1 rapid/NAT2 slow 
genotypes coupled with cigarette smoking jointly increased susceptibility to 
bladder cancer relative to nonsmokers [98]. More recently, Doaei and coworkers 
reported possession of NAT2 G857A SNP combined with CYP1A2 154 A > C 
genetic variant elevated colon and rectal cancer risk, especially among people who 
consumed high levels of meat [99]. However, these previous studies could not 
refer to the role of NAT2 genetic polymorphism in N-acetylation of arylamine 
carcinogens that is considered as the toxification pathway of many environmental 
carcinogens.  
Therefore, we believe use of human hepatocytes containing both NATs and 
CYP1A2 will reflect the interaction between different xenobiotic metabolizing 
enzymes. In addition, NER-deficient UV5-CHO cell lines expressing human 
CYP1A2 and NAT2 alleles will advance the study of functional effects and the 
individual risks associated with NAT2 genetic polymorphism. 
The objective of this study was to compare metabolism and cytotoxicity of 
different xenobiotics in cryopreserved human hepatocytes and CHO cells stably 
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transfected with human CYP1A2 and NAT2. The results could provide further 
evidence that the NAT2 genetic polymorphism modifies aromatic amine‐induced 
mutagenesis and DNA damage and warrant consideration in human risk 
assessments following aromatic amine exposures. 
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MATERIALS AND METHODS 
 
The outline of the experimental design and methods are presented in 
(Figure 8). Human hepatocytes with different NAT2 genotypes were used to 
measure in vitro and in situ N-acetyltransferase activity towards SMZ, ABP, BNA 
and MOCA. Also, CHO cells were stably transfected with CYP1A2 and NAT2*4, 
*5B or *7B and used to measure in vitro and in situ N-acetyltransferase activity 
towards hydralazine, Isoniazid, BNA and MOCA. Cell viability assays were done 
to evaluate the cytotoxicity induced by aromatic amines.  
 
Figure (8): Flow chart of the experimental design and methods 
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SOURCE AND PROCESSING OF CRYOPRESERVED HUMAN 
HEPATOCYTES: 
Cryopreserved human hepatocytes were received from Bioreclamation IVT, 
(Baltimore, MD) and stored in liquid nitrogen until use. Upon removal from liquid 
nitrogen, hepatocytes were thawed according to the manufacturer’s instructions by 
warming a vial of the hepatocytes at 37°C for 90 seconds and transferring to a 50 
mL conical tube containing 45 mL of InVitroGRO HT medium (Bioreclamation IVT). 
The suspension was centrifuged at 50 x g at room temperature for 5 min. The 
supernatant was discarded and cells washed once in ice-cold PBS before lysing 
the cells in ice-cold 20 mM NaPO4, 1 mM dithiothreitol, 1 mM EDTA, 0.2% triton-
X-100, 1 mM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, and 1 µg/mL 
aprotinin. The lysate was centrifuged at 15,000 x g for 20 min and the supernatant 
was aliquoted and stored at -70°C. To mitigate possible instability of human NAT2, 
supernatant aliquots were thawed only once and used immediately to carry out the 
enzymatic reactions. 
DETERMINATION OF NAT2 GENOTYPE AND DEDUCED PHENOTYPE:  
Genomic DNA was isolated from pelleted cells prepared from human 
cryopreserved hepatocyte samples as described above using the QIAamp DNA 
Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer’s instructions. 
NAT2 genotypes and deduced phenotypes were determined as described 
previously [100]. Controls (no DNA) were run to ensure that there was no 
amplification of contaminating DNA (one for each plate) and samples were run 
once for every SNP.
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Individuals possessing two NAT2 alleles associated with rapid acetylation 
activity (NAT2*4) were classified as rapid acetylators; individuals possessing one 
of these alleles and one allele associated with slow acetylation activity (NAT2*5, 
NAT2*6, and NAT2*7) were classified as intermediate acetylators, and those 
individuals that possessed two slow acetylation alleles were classified as slow 
acetylators. Cryopreserved hepatocytes with rapid, intermediate, and slow NAT2 
acetylator genotype were selected at random for measurements of N-acetylation 
as described below.  
 
MEASUREMENT OF SULFAMETHAZINE, ABP, BNA AND MOCA N-
ACETYLTRANSFERASE ACTIVITY IN VITRO:   
N-acetyltransferase assays containing hepatocyte lysate (< 2 mg of 
protein/ml), SMZ (300 μM), ABP (10 – 100 µM), BNA (10 – 100 µM) and MOCA 
(10 – 100 µM) and acetyl coenzyme A (AcCoA) (1000 µM) were incubated at 37°C 
for 10 minutes. Reactions were terminated by the addition of 1/10 volume of 1 M 
acetic acid and the reaction tubes were centrifuged in a small biofuge at 15,000 x 
g for 10 minutes to precipitate protein. The amount of the acetylated products was 
determined following separation and quantitation by high performance liquid 
chromatography (HPLC). For all substrates and their acetylated products, 
separation was accomplished by injection (40µL) onto a 125 x 4 mm Lichrosher 
100 RP-100 5µM C18 HPLC column (Table 2 shows the HPLC parameters for the 
methods used in the current study). The amount of acetyl-SMZ produced was 
determined following separation and quantitation by HPLC as described previously 
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[101]. The amount of acetyl-ABP produced was determined following separation 
and quantitation by high performance liquid chromatography as described 
previously [102]. The amount of acetyl-BNA produced was determined following 
separation and quantitation by HPLC subjected to a gradient of 85% 20 mM 
sodium perchlorate pH 2.5/15% acetonitrile to 35% 20 mM sodium perchlorate pH 
2.5/65% acetonitrile over 10 min, then to 85% 20 mM sodium perchlorate pH 
2.5/15% acetonitrile over 5 min. Retention times for BNA and acetyl-BNA were 
3.97 and 10.1 min respectively. The UV detector was set at 260 nm (Table 2). The 
amount of acetyl-MOCA was determined following separation and quantitation by 
HPLC subjected to a gradient of 100% 20 mM sodium perchlorate pH 2.5/0% 
acetonitrile to 0% 20 mM sodium perchlorate pH 2.5/100% acetonitrile over 10 min, 
then to 100% 20 mM sodium perchlorate pH 2.5/0% acetonitrile over 5 min. 
Retention times for acetyl-MOCA and MOCA were 18.6 and 19.1 min respectively. 
The UV detector was set at 280 nm (Table 2). For all samples, protein 
concentrations were determined using the Bio-Rad protein assay kit (Bio-Rad, 
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Cryopreserved human hepatocytes were selected at random with rapid, 
intermediate, and slow genotypes. Table (3) summarize the different alleles used 













NAT2*4/*4 Rapid 10 8 7 5 
NAT2*4/*5B Intermediate 14 5 6 5 
NAT2*4/*6A Intermediate 8 3 3 2 
NAT2*4/*7B Intermediate 2 0 0 3 
NAT2*5B/*6A Slow 14 5 6 0 
NAT2*5B/*5B Slow 9 2 2 2 
NAT2*6A/*6A Slow 3 0 1 1 
NAT2*7B/*7B Slow 2 2 2 1 




Table (3): The individual NAT2 genotypes used for measurement of in vitro N-




MEASUREMENT OF SULFAMETHAZINE, ABP, BNA AND MOCA N-
ACETYLTRANSFERASE ACTIVITY IN SITU:   
Cryopreserved human hepatocytes previously identified as rapid, 
intermediate, or slow NAT2 acetylator genotypes were thawed as described above 
and transferred to 50 mL conical tubes containing 12 mL of InVitroGRO CP media. 
One mL of hepatocyte/ media mixture was transferred to each well of 12 well 
Biocoat® collagen coated plates to allow cells to attach for 24 hours at 37ºC. 
Following culture in growth media for 24 hours, the cells were washed 3 times with 
500 µL 1X PBS and replaced with media and SMZ, ABP, BNA or MOCA with 
concentrations of 10-100 µM. Hepatocytes were incubated for up to 24 hours after 
which media was removed and protein precipitated by addition of 1/10 volume of 
1 M acetic acid. Media was centrifuged at 15,000 x g for 10 min and the 
supernatant used to separate and quantitate all substrates and their N-acetylated 
products by HPLC as described above (Table 2). 
Cell number was determined after 24 hours of incubation with each 
substrate and activity was calculated in nmoles of acetylated product /24h/million 
cells. Cell number was used to compare the possible toxic effect of each substrate 
on hepatocytes. Also, comparison of that toxic effect was done between the 
different between genotypes. Table (4) summarizes the different alleles used in 



















NAT2*4/*4 Rapid 6 6 6 5 
NAT2*4/*5B Intermediate 4 5 5 5 
NAT2*4/*6A Intermediate 2 1 0 0 
NAT2*4/*7B Intermediate 0 0 0 0 
NAT2*5B/*6A Slow 6 6 5 5 
NAT2*5B/*5B Slow 1 1 1 0 
NAT2*6A/*6A Slow 1 1 1 0 
NAT2*7B/*7B Slow 1 1 1 0 






Table (4): The individual NAT2 genotypes used for in situ N-acetyltransferase 




CHINESE HAMSTER OVARY (CHO) CELL CULTURE: 
The UV5-CHO cell line, a nucleotide excision repair deficient derivative of 
the AA8 line [103], was obtained from the ATCC. Since UV5-CHO lacks nucleotide 
excision repair due to a mutation in the XPD (ERCC2) gene, it is hypersensitive to 
bulky adduct mutagens and belongs to the excision repair cross complementation 
group 2. Cells were grown in alpha-modified minimal essential medium (Cambrex) 
without L-glutamine, ribosides, and deoxyribosides supplemented with 10% fetal 
bovine serum (Hyclone), 100 units/ml penicillin, 100 micrograms/ml streptomycin 
(Cambrex), and 2 mM L-glutamine (Cambrex) at 37 °C in 5% CO2. Media were 
supplemented with appropriate selective agents to maintain stable transfectants. 
CONSTRUCTION AND CHARACTERIZATION OF UV5/CHO CELL LINES: 
The construction of UV5-CHO cells expressing human CYP1A2 and 
NAT2*4, NAT2*5B or NAT2*7B has been reported and characterized [104]. The 
construction scheme is illustrated in (Figure 9). Briefly, pFRT/lacZeo plasmid was 
transfected into nucleotide excision repair deficient UV5 cell lines to generate a 
UV5 cell line containing a single integrated FRT site (UV5FRT). Purified human 
NADPH cytochrome P450 reductase (POR) and CYP1A2 polymerase chain 
reaction (PCR) products were digested and ligated into similarly treated pIRES 
vector and transformed into DH5α competent cells. 
The pIRES plasmid containing cDNAs of human CYP1A2 and POR was 
transfected into the newly established UV5FRT cell line. The colonies of these cells 
were expanded, and intact geneticin-resistant cells were assayed for 7-




undetectable (<0.2 pmoles/min/106 cells) in untransfected UV5 cells, 
whereas CYP1A2-transfected cells (with and without further transfection with 
NAT2) have EROD catalytic activities about 3 pmol/min/106 cells.  
The open reading frames of NAT2*4, NAT2*5B and NAT2*7B were 
amplified by PCR and inserted into the pcDNA5/FRT vector. The pcDNA5/FRT 
plasmid containing human NAT2*4, NAT2*5B, or NAT2*7B was co-transfected 
with pOG44, a Flp recombinase expression plasmid, into UV5FRT/CYP1A2 cells. 
Integration of the pcDNA5/FRT construct into the FRT site was confirmed by PCR. 
The NAT2*4-, NAT2*5B- and NAT2*7B-transfected cells were characterized for N-
acetylation of sulfamethazine, a NAT2-selective substrate. 
 




MEASUREMENT OF HYDRALAZINE, INH, BNA AND MOCA N-
ACETYLTRANSFERASE ACTIVITY IN VITRO:   
N-acetyltransferase assays containing CHO cell lysates of different 
genotypes, hydralazine (10 – 1000 µM), INH (10 – 1000 µM), BNA (10 – 1000 µM) 
and MOCA (10 – 1000 µM) and acetyl coenzyme A (300 – 1000 µM) were 
incubated at 37°C for 60 minutes. Reactions were terminated by the addition of 
1/10 volume of 1 M acetic acid and the reaction tubes were centrifuged in a small 
biofuge at 15,000 x g for 10 minutes to precipitate protein. The amount of the 
acetylated products was determined following separation and quantitation by 
HPLC (Table 2). 
For hydralazine, INH and their acetylated products, separation was 
accomplished by injection (40µL) onto a 250 x 4 mm Discovery 5µM C18 HPLC 
column. Separation of hydralazine and acetyl-hydralazine or 3-methyl-s-triazolo 
[3,4a]-phthalazine (MTP) was done using a gradient of 95% 55 mM sodium 
perchlorate pH 4/5% methanol to 40% 55 mM sodium perchlorate pH 4/60% 
methanol over 20 min, then to 95% 55 mM sodium perchlorate pH 4/5% methanol 
over 3 min. Retention times for hydralazine and MTP were 8.9 and 19.9 min 
respectively. The UV detector was set at 260 nm. 
Separation of INH and acetyl-INH was done using an isocratic gradient of 
90% 25mmol/L sodium phosphate, 20mmol/L heptane sulfonate pH3/10 % 
acetonitrile. Acetyl-INH was quantitated by measuring the absorbance at 266 nm. 




For BNA, MOCA and their acetylated products, separation was 
accomplished by injection (40µL) onto a 125 x 4 mm Lichrosher 100 RP-100 5µM 
C18 HPLC column. The amounts of acetyl-BNA and acetyl-MOCA produced were 
determined using the same methods mentioned before. To determine the apparent 
Km and Vmax for BNA and MOCA, reactions were run in the presence of BNA (7.8 
-1000 µM) or MOCA (100, 200, 300 µM) with fixed concentration of AcCoA (300 
µM).  
For all samples, protein concentrations of cell lysates were determined 
using the Bio-Rad protein assay kit (Bio-Rad, Richmond, CA) and activity was 
calculated in nmoles of acetylated product /ml/min/mg protein.  
 
MEASUREMENT OF BNA AND MOCA N-ACETYLTRANSFERASE ACTIVITY IN 
SITU: 
Cryopreserved CHO cells with different genotypes were thawed and 
transferred to 50 mL conical tubes containing 12 mL of alpha-modified minimal 
essential medium (Cambrex) without L-glutamine, ribosides, and deoxyribosides 
supplemented with 10% fetal bovine serum (Hyclone), 100 units/ml penicillin, 100 
micrograms/ml streptomycin (Cambrex), and 2 mM L-glutamine (Cambrex). One 
mL of cell/ media mixture was transferred to each well of 12 well plates to allow 
cells to attach for 24 hours at 37ºC.  
Following culture for 24 hours, the cells were washed 3 times with 500 µL 




1000 µM. Cells were incubated for up to 24 hours after which media was removed 
and protein precipitated by addition of 1/10 volume of 1 M acetic acid. Media was 
centrifuged at 15,000 x g for 10 min and the supernatant used to separate and 
quantitate all substrates and their acetylated products by HPLC as described 
above. Cell number was determined after 24 hours of incubation with each 
substrate and activity was calculated in nmoles of acetylated product /24h/million 
cells. 
 
Cell viability assay:  
Cytotoxic effect of BNA and MOCA on CHO cell lysates of different 
genotypes was assessed using Alamar Blue test [105]. Briefly, control medium 
was removed; the cells were rinsed with PBS and 2 mL of an Alamar Blue (AB) 
solution (5% [v/v] solution of AB dye) prepared in fresh medium (without FBS or 
supplements) was added to each well. Following 1-hour incubation, AB 
fluorescence was quantified at the respective excitation and emission wavelength 
of 530 and 590 nm using a Tecan Genios microplate reader. The results were 
averaged over 3 different independent experiments (n = 3) with 3 replicates per 
experiment (3 × 12 well plates). Finally, for each plate the reading was also done 
in triplicate (values obtained from 3 different wells were averaged). For each 
experiment, wells containing only the AB solution without cells were also prepared 
and incubated for 1 hour. 





Differences in N-acetylation rates of all substrates among different 
genotypes in hepatocytes and CHO cells were tested for significance by Kruskal-
Wallis test followed by Dunn’s post-hoc test. For kinetics of BNA and MOCA, 
Michaelis–Menten kinetic constants were calculated by linear regression 
























Arylamine N-acetyltransferases (NATs) are xenobiotic metabolizing 
enzymes that play an important role in the metabolism and detoxification of many 
drugs and carcinogens. Two NAT genes (NAT1 and NAT2) have been annotated 
in humans. Both NATs catalyze N- or O-acetylation using AcCoA as a cofactor 
(Figure 10). Our hypothesis is that different NAT2 genotypes affects N-acetylation 
of xenobiotics in cryopreserved human hepatocytes and CHO cells.  
Previous studies in our lab have shown NAT2 genetic polymorphism 
dependent N-acetylation of arylhydrazines as hydralazine [57] and isoniazid [60] 
in human hepatocytes and arylamines as ABP in CHO cells [106]. Also, apparent 
Km and Vmax for SMZ and ABP [37] and for hydralazine [57] were previously 
measured in our lab.  
In the current study, we measured in vitro and in situ NAT2 activity towards 
SMZ (a specific substrate for NAT2 used as a control), ABP, BNA and MOCA in 
cryopreserved human hepatocytes. In addition, we measured in vitro and in situ 
NAT2 activity towards hydralazine, isoniazid, BNA and MOCA in CHO cells stably 
transfected with human CYP1A2 and either NAT2*4 (as rapid acetylator), 
NAT2*5B (as common slow acetylator in Caucasians) or NAT2*7B (as common 




Also, this study included determination of the cytotoxic effect of 
carcinogens: ABP, BNA and MOCA. So, we measured cell viability in human 
hepatocytes exposed to ABP, BNA, or MOCA. For CHO cells, we measured cell 
viability following treatment with BNA and MOCA as ABP induced cytotoxicity was 
previously studied in [106]. Table (5) illustrates a summary of the experiments 
done in the current study. 
 
 
Figure (10): Reactions catalyzed by N-acetyltransferases. Reactions 
(A), (B) and (C) lead to the hydrolysis of acetyl CoA as well as the 
acetylation of the acetyl acceptor molecule. Reactions (A) and (B) 
inactivate the substrate, reactions (C) leads to substrate activation. 
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Figure (15 a) Not included 





































In previous study [57] 
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IN VITRO N-ACETYLTRANSFERASE ACTIVITY IN CRYOPRESERVED 
HUMAN HEPATOCYTES:  
SULFAMETHAZINE (SMZ): 
 
N-acetylation rates towards SMZ in the cryopreserved human hepatocytes 
from rapid, intermediate, and slow NAT2 acetylators were measured using HPLC. 
They exhibited a robust and highly significant NAT2 genotype dependent 
metabolism (P< 0.0001). N-acetylation rate of SMZ was about 2- and 10-fold 
higher in rapid NAT2 acetylators than that of intermediate or slow NAT2 
acetylators, respectively. The highest levels of N-acetylated product were 
observed in rapid acetylator, lower levels in intermediate acetylator, and the lowest 










































Figure (11): In vitro N-acetyltransferase catalytic activities towards SMZ (300 µM). Data illustrates 
box plot of rapid (n=10), intermediate (24), and slow (n=29) acetylators. Individuals possessing two 
NAT2 alleles associated with rapid acetylation activity (NAT2*4) were classified as rapid; individuals 
possessing one of these alleles and one allele associated with slow acetylation activity (NAT2*5, 
NAT2*6, and NAT2*7) were classified as intermediate, and those individuals that possessed two 
slow acetylation alleles were classified as slow. Statistical significance was determined using 
Kruskal-Wallis test followed by Dunn's Multiple Comparison Test. SMZ N-acetyltransferase 










Regarding ABP, N-acetyltransferase activities differed significantly between 
rapid, slow, and intermediate acetylators at 10 µM and 100 µM (p< 0.01). N-
acetylation rate of ABP in rapid acetylators was about 6- and 14-fold higher than 



































































Figure (12): In vitro N-acetyltransferase catalytic activities towards ABP (10-100 µM). Data 
illustrates box plot of rapid (n=8), intermediate (n=8), and slow (n=9) acetylators. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 
Test. ABP N-acetyltransferase activities differed significantly between rapid, intermediate, and slow 
acetylators 10 µM (p= 0.0023; rapid vs. slow p < 0.01 and intermediate vs. slow p< 0.05) or 100 





For BNA, N-acetyltransferase activities differed significantly between rapid, 
slow, and intermediate acetylators at 10 (p< 0.001) and 100 µM (p< 0.01). N-
acetylation rate of BNA in rapid acetylators was about 5- and 6-fold higher than 





































































Figure (13): In vitro N-acetyltransferase catalytic activities towards BNA (10-100 µM). Data 
illustrates box plot of rapid (n=7), intermediate (n=9), and slow (n=11) acetylators. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 
Test. BNA N-acetyltransferase activities differed significantly between rapid, intermediate, and slow 
acetylators at 10 µM (p= 0.0005; rapid vs. slow p < 0.001 and intermediate vs. slow p< 0.05) or 







4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
For MOCA, N-acetyltransferase activities differed significantly between 
rapid, slow, and intermediate acetylators at 10 µM and 100 µM (p< 0.01). N-
acetylation rate of MOCA in rapid acetylators was about 8- and 10-fold higher than 






































































Figure (14): In vitro N-acetyltransferase catalytic activities towards MOCA (10-100 µM). Data 
illustrates box plot of rapid (n=5), intermediate (n=7), and slow (n=7) acetylators. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 
Test. MOCA N-acetyltransferase activities differed significantly between rapid, intermediate, and 
slow acetylators at 10 µM (p= 0.0041; rapid vs. slow p< 0.01) or 100 µM (p= 0.0018; rapid vs. slow 
p< 0.01). 
Figures (11-14) showed in vitro N-acetylation rate of SMZ differed 
significantly among rapid, intermediate, and slow NAT2 acetylators. However, in 
vitro N-acetylation rates of ABP, BNA and MOCA were significantly higher in rapid 




between rapid and intermediate NAT2 acetylators. This difference in N-acetylation 
rates for these carcinogens can affect the individual cancer risk. 
 
 
IN SITU N-ACETYLTRANSFERASE ACTIVITY IN CRYOPRESERVED HUMAN 
HEPATOCYTES: 
In situ N-acetylation rates for SMZ, ABP, BNA, and MOCA in cryopreserved 
hepatocytes was concentration dependent (Figure 15: a, b, c, d).  
For SMZ, BNA and MOCA, there was significant correlation between time 
and the rate of production of the acetylated products at both concentrations 10 and 
100 µM (p< 0.05). The single exception was at BNA 10 µM that can be explained 
with the decreased rate of production of acetylated BNA after 10 hours. Spearman 
Correlation coefficient or r = 1.0 for SMZ at both concentrations (p = 0.0167), r= 
1.0 for BNA 100 µM (p=0.0167) and r= 0.9747 and 1.0 for MOCA 10 and 100 µM, 
respectively (p=0.0167). For ABP, r = 1.0 however, the correlation between time 
and rate of N-acetylation was insignificant at both concentrations (p> 0.05). It is 








































































































































































Figure (15): Concentration- and time-dependent N-acetylation of (a) SMZ, (b) ABP, (c) BNA, and 
(d) MOCA in cryopreserved human hepatocytes in situ. Each data point illustrates the mean ± SD 
of 6 replicates of SMZ, ABP and BNA treated hepatocytes and 5 replicates of MOCA treated 
hepatocytes. Correlation between time and the rate of production of N-acetylated products was 
determined using Spearman’s correlation test. Significant correlation (p< 0.05) was found in case 






Also, the in-situ N-acetylation rates of SMZ, ABP, BNA and MOCA were 
measured using cryopreserved human hepatocytes with different NAT2 genotypes 
and the results are shown below in detail. 
 
Sulfamethazine (SMZ): 
N-acetylation rate of SMZ in rapid acetylators was about 22- and 20-fold 
higher (p< 0.001) than slow acetylator hepatocytes, following incubation with SMZ 













































































Figure (16): N-acetylation rate of SMZ in situ in cryopreserved human hepatocytes from rapid, 
intermediate, and slow acetylators. Data illustrates box plot of rapid (n=6), intermediate (n=6), and 
slow (n=9) acetylators. Statistical significance was determined using Kruskal-Wallis test followed 
by Dunn's Multiple Comparison Test. SMZ N-acetylation rates differed significantly at 10 µM (p= 
0.0005; rapid vs. slow p< 0.01; intermediate vs slow p< 0.01) or at 100 µM (p= 0.0002; rapid vs. 






N-acetylation of ABP differed significantly between rapid and slow; and 
between intermediate and slow acetylators (p< 0.01). N-acetylation rate in rapid 
acetylators was about 6- and 4-fold higher than slow acetylator hepatocytes, 











































































Figure (17): N-acetylation rate of ABP in situ in cryopreserved human hepatocytes from rapid, 
intermediate, and slow acetylators. Data illustrates box plot of rapid (n=6), intermediate (n=6), and 
slow (n=9) acetylators. Statistical significance was determined using Kruskal-Wallis test followed 
by Dunn's Multiple Comparison Test. ABP N-acetylation rates differed significantly at 10 µM (p= 
0.0006; rapid vs. slow p< 0.01; intermediate vs. slow p< 0.01) or at 100 µM (p= 0.0034; rapid vs. 









N-acetylation differed significantly between rapid and slow; and between 
intermediate and slow acetylators (p< 0.01). N-acetylation rate in rapid acetylators 
was about 3- and 4- fold higher than slow acetylator hepatocytes, following 











































































Figure (18): N-acetylation rate of BNA in situ in cryopreserved human hepatocytes from rapid, 
intermediate, and slow acetylators. Data illustrates box plot of rapid (n=6), intermediate (n=5), and 
slow (n=9) acetylators. Statistical significance was determined using Kruskal-Wallis test followed 
by Dunn's Multiple Comparison Test. BNA N-acetylation rates differed significantly at 10 µM (p= 
0.0016; rapid vs. slow p< 0.01; intermediate vs. slow p< 0.05) or at 100 µM (p= 0.0099; rapid vs. 







4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
N-acetylation of MOCA was detected in rapid acetylators. N-acetyl MOCA 
was below detection limit in intermediate and slow acetylators (Limit of detection 












































































Figure (19): N-acetylation rate of MOCA in situ in cryopreserved human hepatocytes from rapid, 
intermediate, and slow acetylators. Data illustrates box plot of rapid (n=5), intermediate (n=5), and 
slow (n=5) acetylators. ND = Not detected (Limit of detection was 13 pmole//24h/million cells) 
 
 
Both in vitro and in situ NAT2 activity assays showed NAT2 genotype 
dependent N-acetylation of carcinogens as ABP, BNA, and MOCA suggesting a 
role of NAT2 genotype polymorphism in modification of cancer risk following 







CELL TOXICITY RESULTS:  
We have measured the percent of cell survival in cryopreserved human 
hepatocytes following treatment with ABP, BNA and MOCA. 
4-AMINOBIPHENYL (ABP): 
Treatment of cryopreserved human hepatocytes using ABP for 24 hours led 
to concentration dependent cytotoxicity in all NAT2 genotypes. Cell survival 
following ABP 100 µM treatment differed significantly (p< 0.05) in all genotypes 
(Figure 20). However, there was no significant difference (p> 0.05) between 
























Figure (20): Cell survival following treatment with ABP. Percent cell survival on the ordinate is 
plotted versus ABP treatment concentration on the abscissa. Statistical significance was 
determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison Test. Each data point 
represents Median for 5 experiments in Rapid (circles), Intermediate (squares), Slow (triangles). 













































Figure (21): Effect of ABP treatment on cell survival: at 10 µM (Top panel) and at 100 µM (Bottom 
panel) in cryopreserved human hepatocytes. Statistical significance was determined using Kruskal-
Wallis test followed by Dunn's Multiple Comparison Test. Data illustrates box plot of 5 experiments. 






Treatment of cryopreserved human hepatocytes using BNA for 24 hours 
led to concentration dependent cytotoxicity in all NAT2 genotypes. Cell survival 
following BNA 100 µM treatment differed significantly in all genotypes (p< 0.05) 
(Figure 22). However, there was no significant difference (p> 0.05) between 


























Figure (22): Cell survival following treatment with BNA. Percent cell survival on the ordinate is 
plotted versus BNA treatment concentration on the abscissa. Statistical significance was 
determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison Test. Each data point 
represents Median for 5 experiments in Rapid (circles), Intermediate (squares), Slow (triangles). 
For all genotypes, cell survival differed significantly following treatment 100 µM. 














































Figure (23): Effect of BNA treatment on cell survival: at 10 µM (Top panel) and at 100 µM (Bottom 
panel) in cryopreserved human hepatocytes. Statistical significance was determined using Kruskal-
Wallis test followed by Dunn's Multiple Comparison Test. Data illustrates box plot of 5 experiments. 





4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
Treatment of cryopreserved human hepatocytes using MOCA for 24 hours 
led to concentration dependent cytotoxicity in all NAT2 genotypes. Cell survival 
following MOCA 100 µM treatment differed significantly (p< 0.05 in all genotypes) 
(Figure 24). However, there was no significant difference (p> 0.05) between 



























Figure (24): Cell survival following treatment with MOCA. Percent cell survival on the ordinate is 
plotted versus MOCA treatment concentration on the abscissa. Statistical significance was 
determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison Test. Each data point 
represents Median for 5 experiments in Rapid (circles), Intermediate (squares), Slow (triangles). 
For all genotypes, cell survival differed significantly following treatment with 100 µM. 














































Figure (25): Effect of MOCA treatment on cell survival: at 10 µM (Top panel) and at 100 µM (Bottom 
panel) in cryopreserved human hepatocytes. Statistical significance was determined using Kruskal-
Wallis test followed by Dunn's Multiple Comparison Test. Data illustrates box plot of 5 experiments. 





IN VITRO N-ACETYLTRANSFERASE ACTIVITY IN CHINESE HAMSTER 
OVARY (CHO) CELLS: 
For hydralazine, INH, BNA and MOCA, in vitro NAT2 activity was done 
using three different concentrations: 10, 100, 1000 µM and AcCoA 300 and 1000 
µM to investigate the role of NAT2 genotype polymorphism in N-acetylation. N-
acetyltransferase activities were normalized to reaction minutes and mg protein. 
 
HYDRALAZINE: 
For Hydralazine 10 µM or 100 µM and AcCoA 300 µM, NAT2 catalytic in 
UV5/CYP1A1/NAT2*4 cells was line was about 5-fold higher than 
UV5/CYP1A1/NAT2*7B cells (p< 0.05). For Hydralazine 1000 µM and AcCoA 300 
µM, NAT2 catalytic activity in UV5/CYP1A1/NAT2*4 cells was about 4-fold higher 















































































































































Figure (26): N-acetylation rate of hydralazine in vitro in CHO cell lines using AcCoA 300 µM. 
Statistical significance was determined using Kruskal-Wallis test followed by Dunn's Multiple 




For hydralazine 10 µM and AcCoA 1000 µM, No significant difference 
between N-acetylation rate of hydralazine in the three genotypes (p> 0.05). For 
hydralazine 100 or 1000 µM and AcCoA 1000 µM, NAT2 catalytic activity in 
UV5/CYP1A1/NAT2*4 cells was about 13-fold higher than UV5/CYP1A1/NAT2*7B 











































































































































Figure (27): N-acetylation rate of hydralazine in vitro in CHO cell lines using AcCoA 1000 µM. 
Statistical significance was determined using Kruskal-Wallis test followed by Dunn's Multiple 





For isoniazid 10 µM and AcCoA 300 µM, NAT2 catalytic was undetected in 
all CHO cell lines (The detection limit was 0.1 pmole/min/mg). For isoniazid 100 
µM and AcCoA 300 µM, NAT2 catalytic activity in UV5/CYP1A1/NAT2*4 cells was 
about 4-fold higher than UV5/CYP1A1/NAT2*5B cells (p< 0.05) while there is no 
detectable activity in UV5/CYP1A1/NAT2*7B cell line. For isoniazid 1000 µM and 
AcCoA 300 µM, NAT2 catalytic activity in UV5/CYP1A1/NAT2*4 cells was about 










































































































Figure (28): N-acetylation rate of isoniazid in vitro in CHO cell lines using AcCoA 300 µM. Statistical 
significance was determined using Unpaired T-test (INH 100 µM) and Kruskal-Wallis test followed 
by Dunn's Multiple Comparison Test (INH 1000 µM). Data illustrates box plot of three replicates.  
*= p< 0.05, ND= not detected (The detection limit was 0.1 pmole/min/mg) 
 
 
For AcCoA 1000 µM, NAT2 catalytic activity in UV5/CYP1A1/NAT2*4 cells 
was 4-, 11- 12- fold higher than in UV5/CYP1A1/NAT2*7B cells with isoniazid 10, 







































































































































Figure (29): N-acetylation rate of isoniazid in vitro in CHO cell lines using AcCoA 1000 µM. 
Statistical significance was determined using Kruskal-Wallis test followed by Dunn's Multiple 




N-acetylation rates of hydralazine and INH differed significantly between 
UV5/CYP1A1/NAT2*4 cells (contains rapid NAT2 allele) and 
UV5/CYP1A1/NAT2*7B but not UV5/CYP1A1/NAT2*5B although both contain 




In vitro BNA NAT2 activity was not detected in the UV5 and UV5/CYP1A1 
cell lines (Limit of detection was 0.03 pmoles/min/mg). 
For BNA 10 µM or 100 µM and AcCoA 300 µM, NAT2 catalytic activity 
towards BNA in UV5/CYP1A1/NAT2*4 cells was about 7-fold higher than in the 
UV5/CYP1A1/NAT2*5B cells (p< 0.05). For BNA 1000 µM and AcCoA 300 µM, 
NAT2 catalytic activity towards BNA in UV5/CYP1A1/NAT2*4 cells was about 4-
fold higher than the UV5/CYP1A1/NAT2*5B cells (p< 0.05). In all BNA 
concentrations, there was no significant difference between 
















































































































































Figure (30): N-acetylation rate of BNA in vitro in CHO cell lines using AcCoA 300 µM. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 




For BNA 10 µM and AcCoA 1000 µM, NAT2 catalytic activity towards BNA 
in UV5/CYP1A1/NAT2*4 cells was about 37-fold higher than in the 
UV5/CYP1A1/NAT2*7B cells (p< 0.05). For BNA 100 µM and AcCoA 1000 µM, 
NAT2 catalytic activity towards BNA in UV5/CYP1A1/NAT2*4 cells was about 9-
and 14-fold higher than in the UV5/CYP1A1/NAT2*5B and UV5/CYP1A1/NAT2*7B 
cell lines respectively (p< 0.05). For BNA 1000 µM and AcCoA 1000 µM, NAT2 
catalytic activity towards BNA in UV5/CYP1A1/NAT2*4 cells was about 8-and 9-
fold higher than in the UV5/CYP1A1/NAT2*5B and UV5/CYP1A1/NAT2*7B cell 
lines respectively (p< 0.05). In all BNA concentrations, there was no significant 
difference between UV5/CYP1A1/NAT2*5B and UV5/CYP1A1/NAT2*7B cell lines 



















































































































































Figure (31): N-acetylation rate of BNA in vitro in CHO cell lines using AcCoA 1000 µM. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 




4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA:  
For MOCA 10 µM or 100 µM and AcCoA 300 µM, in vitro NAT2 catalytic 
activity towards MOCA in UV5/CYP1A1/NAT2*4 cells was about 4-fold higher than 
in the UV5/CYP1A1/NAT2*5B cells (p< 0.05). For MOCA 1000 µM and AcCoA 300 
µM, NAT2 catalytic activity towards MOCA had no significant difference between 
the three genotypes (p> 0.05). Also, increasing MOCA concentration from 100 µM 
to 1000 µM with steady AcCoA concentration did not lead to further increase in the 

















































































































































Figure (32): N-acetylation rate of MOCA in vitro in CHO cell lines using AcCoA 300 µM. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 




For MOCA 10, 100 or 1000 µM and AcCoA 1000 µM, NAT2 catalytic activity 
towards MOCA showed no significant difference between the three genotypes (p> 















































































































































Figure (33): N-acetylation rate of MOCA in vitro in CHO cell lines using AcCoA 1000 µM. Statistical 
significance was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison 




In vitro N-acetylation rates of hydralazine and isoniazid showed higher level 
in NAT2*4 compared to NAT2*7B not NAT2*5B although both are slow. For BNA, 
CHO cells expressing NAT2*5B and NAT287B showed different significance when 
compared to NAT2*4. At AcCoA 300 µM, N-acetylation rate in NAT2*4 was 
significantly higher than NAT2*5B and not NAT2*7B. However, at AcCoA 1000 
µM, N-acetylation rate of NAT2*4 was significantly higher than both NAT2*5B and 
NAT2*7B. For MOCA, NAT2*4 is significantly higher than NAT2*5B and not 
NAT2*7B. All these finding suggest N-acetylation rate of some substrates differ 


















KINETICS OF CHO CELLS EXPRESSING NAT2*4, NAT2*5B AND NAT2*7B: 
Previous studies have measured apparent Km and Vmax of SMZ, ABP [37], 
and hydralazine [57]. Table (6) summarizes the apparent Km and Vmax of SMZ, 
ABP and hydralazine previously reported by our lab. 
 






SMZ [37] 116 11.5 
ABP [37] 25.8 ± 3.1 2.41 ± 0.16 
Hydralazine [57] 20.1 ± 8.8  153 ± 15 
 
 
In the current study, Kinetics of BNA and MOCA acetylation were tested in 
CHO cells expressing NAT2*4, NAT2*5B or NAT2*7B  
 
BNA KINETICS:  
To determine apparent Km and Vmax values for BNA, in vitro N-
acetyltransferase reactions were run in the presence of a range of BNA (7.8–1000 
µM) and fixed concentration of AcCoA (300 µM). Apparent Km did not vary 




However, Vmax which is the rate of production of acetylated BNA for 
UV5/CYP1A1/NAT2*4 cells was about 7-fold greater (p< 0.05) than in the 
UV5/CYP1A1/NAT2*5B cell line (Table 7, Figure 34). 
 
Table (7): Kinetic parameters for BNA acetylation by NAT2*4, NAT2*5B and 







NAT2*4 9.65 ± 2.7 0.0522 ± 0.0032 
NAT2*5B 9.2 ± 1.8 0.0078 ± 0.0003 





























































































Figure (34): Different CHO cells genotypes affinity towards BNA. No significant difference in 
apparent Km between NAT2*4, NAT2*5B and NAT2*7B (Top panel). The rate of production of N-
Acetyl BNA was lower in NAT2*5B than NAT2*4 as indicated by the lower Vmax (Bottom panel). 
Statistical significance was determined using Kruskal-Wallis test followed by Dunn's Multiple 





To determine apparent Km and Vmax values for MOCA, in vitro N-
acetyltransferase reactions were run in the presence of a range of MOCA (25–300 
µM) and fixed concentration of AcCoA (300 µM). Apparent Km values of MOCA did 
not vary significantly between NAT2*4, NAT2*5B and NAT2*7B (p> 0.05).  
However, Vmax which is the rate of production of acetylated MOCA for 
UV5/CYP1A1/NAT2*4 cells was about 42-fold higher (p< 0.05) than in the 
UV5/CYP1A1/NAT2*7B cell line (Table 8 and Figure 35). 
 








NAT2*4 16.04 ± 5.2 0.0849 ± 0.0022 
NAT2*5B 37.72 ± 30.54 0.0026 ± 0.0004 


























































































Figure (35): Different CHO cells genotypes affinity towards MOCA. No significant difference in 
apparent Km between NAT2*4, NAT2*5B and NAT2*7B (Top panel). The rate of production of N-
Acetyl MOCA was lower in NAT2*7B than NAT2*4 as indicated by the lower Vmax (Bottom panel). 
Statistical significance was determined using Kruskal-Wallis test followed by Dunn's Multiple 





IN SITU N-ACETYLTRANSFERASE ACTIVITY IN CHINESE HAMSTER OVARY 
(CHO) CELLS: 
In the current study, we have used CHO cells expressing CYP1A2 and 
NAT2*4, NAT2*5B or NAT2*7B to measure in situ N-acetyltransferase activity 
towards BNA and MOCA. Future studies are needed to measure in situ N-
acetylation for other substrates: SMZ, ABP, hydralazine and INH in CHO cells.  
 
β-NAPHTHYLAMINE (BNA): 
For BNA 10 µM and 100 µM NAT2 catalytic activity towards BNA in 
UV5/CYP1A1/NAT2*4 cells was about 8- and 9-fold higher, respectively than in 
the UV5/CYP1A1/NAT2*5B cell line (p< 0.05). For BNA 1000 µM, NAT2 catalytic 
activity towards BNA showed no significant difference between the three cell lines 


















































































































































Figure (36): N-acetylation rate of BNA in situ in CHO cell lines. Statistical significance was 
determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison test. Data box plot 




4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
For MOCA 10 µM and 100 µM, NAT2 catalytic activity towards MOCA in 
UV5/CYP1A1/NAT2*4 cells was about 30- and 39- fold higher than in the 
UV5/CYP1A1/NAT2*5B cell line (p< 0.05) (Figure 37). However, for MOCA 1000 










































































































Figure (37): N-acetylation rate of MOCA in situ in CHO cell lines. Statistical significance was 
determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison test. Data illustrates 




CELL VIABILITY ASSAY: 
Arylamine carcinogens can induce cytotoxicity and/or genotoxicity. 
Previous study, done in our lab, showed that arylamine carcinogens as ABP and 
AF have cytotoxic effect on CHO cells [91]. In the current study, we treated CHO 
cells with BNA and MOCA for 24 hours then alamar blue assay was done to 
measure percent of cell viability. 
 
β-NAPHTHYLAMINE (BNA): 
BNA (10-1000 µM) treatment for 24 hours resulted in dose-dependent 
reduction in the viability of the UV5/CYP1A1/NAT2*4, UV5/CYP1A1/NAT2*5B and 
UV5/CYP1A1/NAT2*7B transfected CHO cell lines. Cell survival following BNA 
1000 µM treatment differed significantly (p< 0.05 in all cell lines) (Figure 38). 
However, there was no significant difference (p> 0.05) between different 































Figure (38): Cell viability in CHO cell lines following treatment with BNA. Percent cell viability on 
the ordinate is plotted versus BNA treatment concentration on the abscissa. Statistical significance 
was determined using Kruskal-Wallis test followed by Dunn's Multiple Comparison test. Each data 
point represents Median for three experiments in UV5/CYP1A1/NAT2*4 (circles), 
UV5/CYP1A1/NAT2*5B (squares), UV5/CYP1A1/NAT2*7B (triangles). For all cell lines, cell 
viability differed significantly following treatment with 1000 µM. 














































































Figure (39): Effect of BNA treatment on cell viability: at 100 µM (Top panel) and at 1000 µM (Bottom 
panel) in CHO cell lines. Statistical significance was determined using Kruskal-Wallis test followed 
by Dunn's Multiple Comparison test. Data illustrates box plot of three experiments. There was no 









4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA: 
Treatment of CHO cells using MOCA (10-1000 µM) for 24 hours resulted in 
dose-dependent reduction in viability of the UV5/CYP1A1/NAT2*4, 
UV5/CYP1A1/NAT2*5B and UV5/CYP1A1/NAT2*7B transfected CHO cell lines. 
Cell survival following MOCA 1000 µM treatment differed significantly (p< 0.05 in 
all cell lines) (Figure 40). However, there was no significant difference between 




























Figure (40): Cell viability in CHO cell lines following treatment with MOCA. Percent cell viability on 
the ordinate is plotted versus MOCA treatment concentration on the abscissa. Each data point 
represents Each data point represents Median for three experiments in UV5/CYP1A1/NAT2*4 
(circles), UV5/CYP1A1/NAT2*5B (squares), UV5/CYP1A1/NAT2*7B (triangles). For all cell lines, 
cell viability differed significantly following treatment 100-1000 µM. 














































































Figure (41): Effect of MOCA treatment on cell viability: at 100 µM (Top panel) and at 1000 µM 
(Bottom panel) in CHO cell lines. Statistical significance was determined using Kruskal-Wallis test 
followed by Dunn's Multiple Comparison test. Data illustrates box plot of three experiments. There 







Human NAT2 genotype and phenotype relationship is well established in 
previous studies, and it is documented as a gene dosage relationship. Following 
recombinant expression of human NAT2 alleles in bacteria and yeast, NAT2*4 
allele is the reference allele with high activity, NAT2*5 allele showed the greatest 
reduction in N-acetylation, followed by the NAT2*14 allele cluster followed by the 
NAT2* 6 cluster followed by the NAT2* 7 cluster [108, 109]. However, more recent 
studies in cryopreserved human hepatocytes have shown that the N-
acetyltransferase activity is lower in hepatocytes homozygous for NAT2*6A than 
NAT2*5B [110]. Due to these variable findings, we need more lab based 
experimental studies thus providing better understanding the role of NAT2 genetic 
variants. The objective of the present study was to investigate the effect of different 
NAT2 genotypes on N-acetylation of SMZ, hydralazine, INH, ABP, BNA and 
MOCA in cryopreserved human hepatocytes expressing different rapid, 
intermediate and slow NAT2 alleles and CHO cells expressing NAT2*4 (as rapid 
acetylator) NAT2*5B and NAT2*7B (as slow acetylators). It is our hypothesis that 
N-acetylation rates of these xenobiotics are NAT2-genotype dependent and that 





N-ACETYLATION IN CRYOPRESERVED HUMAN HEPATOCYTES: 
The trimodal capacity of N-acetylation of many drugs and carcinogens 
metabolized by NAT2 has been previously identified in cryopreserved human 
hepatocytes both in vitro and in situ. Doll et al., [3] reported SMZ N-
acetyltransferase catalytic activities carried out at 300 µM in vitro differed 
significantly with respect to the NAT2 acetylator genotype.  
SULFAMETHAZINE (SMZ): 
In the current study, in vitro N-acetylation of SMZ as an aromatic amine drug 
yielded rapid, intermediate, and slow acetylator phenotypes (p< 0.0001) (Figure 
11). This is consistent with the trimodal (rapid, intermediate, and slow) distribution 
of N-acetylation capacity in human populations mentioned before for SMZ [111]. 
However, for in situ N-acetylation of SMZ, there was no significant difference 
between the rapid and intermediate acetylators at 10 or 100 µM (Figure 16). It is 
possible SMZ N-acetylation in situ was not NAT2-genotype dependent might be 
due to use of SMZ at concentrations that were below the apparent KM for 
recombinant human NAT2 previously reported by our lab [37].  
ABP, BNA and MOCA are arylamine procarcinogens that undergo N- and/or 
O- acetylation catalyzed by NAT1 and NAT2. However, human NAT2 has a three- 
to four-fold higher affinity than NAT1 for urinary bladder carcinogens such as ABP, 
BNA and MOCA [10, 112]. This finding is consistent with our hypothesis that NAT2 
genetic polymorphism in cryopreserved human hepatocytes and CHO cells can 




our lab have used a congenic Syrian hamster model that showed NAT2 acetylation 
polymorphism clearly sequestered the N-acetylation of urinary bladder 
carcinogens such as ABP and BNA into three phenotypes in hepatic and 
extrahepatic tissues [113, 114]. 
 
4-AMINOBIPHENYL (ABP): 
For ABP, a previous study reported in vitro N-acetylation of ABP (1 mM) in 
hepatocytes among rapid acetylators was 2-fold higher than slow acetylators. This 
suggests NAT2 polymorphism may have a modest impact on ABP metabolism [3]. 
In the current study, N-acetylation rates in the cryopreserved human hepatocytes 
from rapid, intermediate, and slow NAT2 acetylators exhibited NAT2 genotype-
dependent N-acetylation of ABP. In vitro ABP NAT activities differed significantly 
between rapid and slow acetylators at 10 μM or 100 μM (P = 0.0023) (Figure 12). 
Moreover, the differences between rapid and slow acetylator hepatocytes were 
more robust at 10 μM (8-fold) and 100 μM (6-fold) than previously reported at 1 
mM (two-fold) [3]. N-acetylation of ABP in situ also differed significantly between 
human hepatocytes from rapid and slow acetylators at 10 μM (about 5-fold, p = 
0.0006) and 100 μM (about 4-fold, p = 0.0034) (Figure 17).  
These findings are the first to be reported for an aromatic amine carcinogen 
in human hepatocytes that mirror those recently reported for therapeutic drugs 
such as hydralazine [57], isoniazid [60] and solithromycin [115]. A previous study 




shown the effect of NAT2 acetylation polymorphism on ABP-induced genotoxicity 
in the form of DNA adducts and mutants. Cells transfected with NAT2*4 allele 
(rapid acetylator) showed higher levels of N-acetylation and mutagenicity than cells 
transfected with NAT2*5B or NAT2*7B (slow acetylators). 
 
β-NAPHTHYLAMINE (BNA): 
In the current study, in vitro N-acetylation of BNA varied significantly among 
rapid, intermediate, and slow NAT2 genotypes at 10 μM (p = 0.0005) or 100 μM (p 
= 0.0013) (Figure 13). The highest levels were observed in rapid acetylator, lower 
levels in intermediate acetylator, and the lowest levels in slow acetylator 
hepatocytes. Moreover, the differences between rapid and slow acetylator 
hepatocytes were more robust at 10 μM (7-fold, p< 0.001) than 100 μM (3.5-fold, 
p< 0.01). Also, in situ N-acetylation of BNA differed significantly between rapid, 
intermediate, and slow NAT2 genotypes at 10 μM (p = 0.0016) or 100 μM (p = 
0.0099) (Figure 18).  
BNA N-acetylation in humans has yet to be investigated or reported, but our 
findings clearly show NAT2 genotype dependent BNA N-acetylation as previously 
shown for N-acetylation of other arylamine carcinogens such as 2-aminofluorene, 
4-aminobiphenyl and benzidine [116, 117]. Previous studies investigated N-
acetylation of BNA using rabbit or rat hepatocytes and they showed N-acetylation 
is the major pathway for BNA metabolism and N-oxidation is a minor pathway [94, 




hepatocytes to investigate the effect of NAT2 genetic polymorphism on N-
acetylation of BNA. 
 
4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA:  
Also, in vitro N-acetylation of MOCA differed significantly among rapid and 
slow acetylator genotypes at 10 μM (P = 0.0041) or 100 μM (P = 0.0018). The 
highest levels were observed in rapid acetylator, lower levels in intermediate 
acetylator, and the lowest levels in slow acetylator hepatocytes. The differences 
between rapid and slow acetylator hepatocytes were about 7-fold (p< 0.01) at 10 
μM and 8-fold (p< 0.01) at 100 μM (Figure 14). This is consistent with a previous 
study performed by our lab in which we observed a highly significant (p < 0.0001) 
gene dose-response relationship between NAT2 genotype polymorphism and in 
vitro N-acetylation of MOCA using cryopreserved human hepatocytes and MOCA 
300 μM [71]. In our current study, in situ N-acetylation of MOCA was not detectable 
in intermediate and slow acetylators incubated with 10 or 100 μM (Figure 19). 
Further studies are needed to explain that.  
The N-acetylation activity of all three arylamine procarcinogens (i. e., ABP, 
BNA or MOCA) across all NAT2 genotypes was lower than SMZ N-acetylation 
activity (Figures 11-14). Although N-acetylation of these carcinogens was 
significantly higher in rapid NAT2 acetylators compared to slow NAT2 acetylators. 
However, there were no significant differences in N-acetylation of carcinogens 




SMZ. This insignificant difference can be explained with the fact of catalysis of 
arylamine carcinogens by NAT1 in addition to NAT2. NAT1 with its variant alleles 
is considered as additional factor that affects N-acetylation of these carcinogens 
[10, 71]. Future studies will assess the role of NAT1 different alleles in N-
acetylation of these carcinogens. 
Furthermore, we found in situ N-acetylation rates of SMZ, BNA and MOCA 
were both time and concentration dependent in situ in cryopreserved human 
hepatocytes (Figure 15). The single exception was at BNA 10 μM where the N-
acetylation rate for BNA µM started to decrease after 6 hours suggesting additional 
studies are needed at shorter time points. This is consistent with other previously 
described studies for isoniazid and hydralazine that showed an increase in the N-
acetylation rate with increase in concentration and incubation time in 
cryopreserved human hepatocytes [57, 60]. For ABP, the correlation between time 
and rate of production of acetylated ABP was insignificant at both concentrations 
(p> 0.05). It is likely that the rate of reaction started to decrease over time due to 
ABP consumption. 
Previous studies demonstrated aromatic amines such as ABP and BNA can 
induce cytotoxicity in bacteria [118], rabbit hepatocytes [94] or CHO cells 
expressing human NAT2 [91, 106]. To our knowledge, the current study is the first 
study to investigate the cytotoxic effects of aromatic amines in human hepatocytes. 
Our findings showed treatment of cryopreserved human hepatocytes using ABP, 
BNA or MOCA for 24 hours led to concentration dependent cytotoxicity in all NAT2 




genotypes except for BNA at 100 µM (Figures 21, 23, 25) suggesting ABP, BNA, 
MOCA might induce cytotoxicity in human hepatocytes regardless of the NAT2 
acetylator status. 
 
N-ACETYLATION IN CHINESE HAMSTER OVARY (CHO) CELLS: 
Chinese hamster ovary or CHO cells are considered a good model to 
display the different human NAT2 genotypes and how this can affect N-acetylation 
of different drugs and carcinogens. This model is a good fit for our study for many 
reasons. First, CHO cells enabled stable expression of human NAT2 alleles so 
they can reveal the individual role of NAT2 in N-acetylation independent of NAT1. 
Next, they enable stable expression of CYP1A2 which is a keystone for activation 
of these carcinogens through N-hydroxylation and further O-acetylation by NAT2. 
Last, they lack nucleotide excision repair or NER due to a mutation in the XPD 
(ERCC2) gene. This lack of NER makes the CHO cells hypersensitive to bulky 
DNA adducts and mutagens [91]. This characteristic allows us to capture 
CYP1A2/NAT2 dependent genotoxic effects. 
In the current study, we used CHO cells transfected with human CYP1A2 
and either human NAT2*4 (rapid acetylator), NAT2*5B (common Caucasian slow 
acetylator), or NAT2*7B (common Asian slow acetylator) alleles. We have tested 
hydralazine and isoniazid as examples of drugs and BNA and MOCA as examples 






For hydralazine, using AcCoA concentration of 300 or 1000 µM, 
UV5/CYP1A1/NAT2*4 has higher N-acetylation rate than UV5/CYP1A1/NAT2*7B 
not UV5/CYP1A1/NAT2*5B although both later alleles are considered slow NAT2 
alleles. (Figure 26, 27). This can be explained by the presence of NAT2 SNP 
G857A which is characteristic of NAT2*7 allele. This SNP might influence the 
accessibility of some substrates and AcCoA, leading to substrate-dependent 
activity changes observed here and in previous studies [109,119,120]. Zang and 
coworkers showed that G857A SNP displayed an 8-fold lower apparent Km to SMZ 




For isoniazid, UV5/CYP1A1/NAT2*4 had higher in vitro N-acetylation rate 
compared to UV5/CYP1A1/NAT2*5B and UV5/CYP1A1/NAT2*7B at both 300 µM 
AcCoA. At 1000 µM AcCoA, UV5/CYP1A1/NAT2*4 had higher in vitro N-
acetylation rate compared to UV5/CYP1A1/NAT2*7B and not 








In vitro NAT2 activity towards BNA using AcCoA 300 µM showed significant 
differences in N-acetylation rates between UV5/CYP1A1/NAT2*4 and 
UV5/CYP1A1/NAT2*5B and not UV5/CYP1A1/NAT2*7B. Also, N-acetylation rate 
of UV5/CYP1A1/NAT2*7B increased with increase in BNA concentration. (Figure 
30). However, at AcCoA concentration 1000 µM, N-acetylation rate was 
significantly higher in UV5/CYP1A1/NAT2*4 compared to UV5/CYP1A1/NAT2*5B 
and UV5/CYP1A1/NAT2*7B. Also, no remarkable increase in N-acetylation rate by 
increasing BNA concentration (Figure 31). This suggest N-acetylation rate of BNA 
is AcCoA dependent even within the same slow genotype. 
This can be explained with different BNA and AcCoA kinetics between 
different slow NAT2 alleles. To investigate that, we measured the apparent Km and 
Vmax for BNA in CHO cells. Our findings showed that UV5/CYP1A1/NAT2*7B had 
an apparent Km of 130.9 µM value which is about 13-fold higher than that of the 
other two genotypes reflecting the lower affinity of UV5/CYP1A1/NAT2*7B towards 
BNA. However, Vmax which is the rate of production of N-acetyl BNA for 
UV5/CYP1A1/NAT2*4 cells was about 5.5-fold higher (p< 0.05) than in the 
UV5/CYP1A1/NAT2*5B cell line. On the other hand, there was no significant 
difference in Vmax for the UV5/CYP1A1/NAT2*4 and UV5/CYP1A1/NAT2*7B cell 
lines (Table 7, Figure 34).  
For AcCoA kinetics, we propose NAT2*7B has a lower Km for AcCoA. So, 
at AcCoA 300 uM, NAT2*7B can bind to AcCoA leading to N-acetylation rate close 




AcCoA concentration, NAT2*5B can bind more effectively to AcCoA. So, further 
studies are required to confirm the impact of different NAT2 alleles on the AcCoA 
Km in CHO cells. 
In situ N-acetylation rates of BNA were measured following treatment of 
CHO cells with BNA 10-1000 µM for 24 hours. For BNA, NAT2 catalytic activity in 
UV5/CYP1A1/NAT2*4 cells was about 8-fold and 9-fold higher (p< 0.05) than in 
the UV5/CYP1A1/NAT2*5B cell line at 10 and 100 µM, respectively. Increasing 
BNA concentration led to further increase in N-acetylation in 
UV5/CYP1A1/NAT2*7B to the extent that was close to UV5/CYP1A1/NAT2*4 at 
1000 µM (Figure 36). This is consistent with the in vitro BNA N-acetylation results 
in CHO cells using AcCoA 300 µM (Figure 30). 
Treatment of CHO cells with BNA (10-1000 µM) for 24 hours resulted in 
concentration-dependent reduction in the viability of all CHO cell lines. Cell viability 
following BNA 1000 µM treatment differed significantly (p< 0.05) in all cell lines 
(Figure 38). No significant difference was observed in cell viability between the 
different genotypes (p> 0.05) suggesting NAT2 genotype may not be the only 
determinant of aromatic amines induced cytotoxicity in these cell lines (Figure 39).  
 
4, 4’-METHYLENE BIS (2-CHLOROANILINE) OR MOCA:  
For MOCA 10 and 100 µM, in vitro N-acetylation rate in 
UV5/CYP1A1/NAT2*4 cells was significantly about 4-fold higher than that in 




Although N-acetylation rate in UV5/CYP1A1/NAT2*7B was higher than that of 
UV5/CYP1A1/NAT2*5B using AcCoA 300 µM, the difference was not significant 
(Figures 32). 
For MOCA kinetics, there was no significant difference in apparent Km 
between the three genotypes UV5/CYP1A1/NAT2*4, UV5/CYP1A1/NAT2*5B and 
UV5/CYP1A1/NAT2*7B. However, the rate of production of N-acetylated MOCA 
or Vmax for UV5/CYP1A1/NAT2*4 cells was about 42-fold higher (p< 0.05) than 
in the UV5/CYP1A1/NAT2*7B cell line (Table 8 and Figure 35).  
In situ NAT2 activity towards MOCA showed there was significant difference 
in N-acetylation rates between UV5/CYP1A1/NAT2*4 and UV5/CYP1A1/NAT2*5B 
and not UV5/CYP1A1/NAT2*7B cell lines at 10 and 100 µM (Figure 37). Also, there 
was decrease in the amount of the acetylated product while MOCA concentration 
increased. This can be explained with cytotoxicity at MOCA 100 µM (cell viability 
was about 65%). N-acetylation of MOCA at 1000 µM could not be measured due 
to significant loss of cell viability at 1000 µM (cell viability was about 3-5%). 
Treatment of CHO cells with MOCA (10-1000 µM) for 24 hours resulted in 
concentration-dependent reduction in the viability of all CHO cell lines. Cell viability 
following MOCA 1000 µM treatment differed significantly (p< 0.05) in all cell lines 
(Figure 40). As BNA, no significant difference (p> 0.05) was observed in cell 
viability between the different genotypes following MOCA treatment (Figure 41).  
These results are consistent with epidemiological studies. For instance, a 




acetylation phenotype was significantly associated with an increased risk of 
bladder cancer [122]. In addition, a meta-analysis, that included studies from 
different populations, indicated a possible association between the slow NAT2 
genotype, occupational exposure to aromatic amines or polycyclic aromatic 
hydrocarbons, and development of bladder cancer in different populations [123]. 
It also seems that possession of the slow NAT2 genotype and exposure to 
smoke derived carcinogens such as ABP and BNA jointly modify the risk of 
developing bladder cancer relative to nonsmoker slow acetylators [124].  
Moreover, our findings in CHO cells expressing human NAT2*5B and 
NAT2*7B refer to the probability of heterogenicity within the same slow NAT2 
genotype as both alleles had different N-acetylation activity while decreasing the 
AcCoA concentration. This is consistent with previous study done in our lab that 
showed NAT2 catalytic activity towards ABP was lower than the 
UV5/CYP1A1/NAT2*5B cell line when compared to the cell line expressing 
UV5/CYP1A1/NAT2*7B [106]. In addition, a clinical study done in 504 north 
American subjects of Caucasian origin indicated there were variations in the N-
acetylation NAT2 status among slow acetylator individuals. NAT2*6/*6 
homozygotes had about 30% reduction in enzyme activity as compared to 
NAT2*5/*5 homozygotes although both are considered slow acetylators [93]. 
NAT2 genotypes used in the present study did not affect cytotoxicity in CHO 
cells following BNA or MOCA exposure. However, further lab-based studies can 
determine the genotoxicity or mutagenicity induced by aromatic amines and its 




CONCLUSIONS AND SUMMARY 
 
STRENGTHS OF THIS WORK: 
Although previous studies were done in bacteria, rabbit, or rat hepatocytes 
to study the effect of NAT2 genetic polymorphism on metabolism of xenobiotics, 
they are not accurate enough to anticipate the metabolic profile of xenobiotics in 
humans. In this study, we have used cryopreserved human hepatocytes that 
contain a combination of drug metabolizing enzymes including CYP1A2 and both 
NATs. They provide the closest in vitro model to human liver to study the effect of 
different NAT2 genes on N-acetylation of arylamines carcinogens (e.g. ABP, BNA 
and MOCA) that are hazardous to be studied in humans. Also, we have utilized 
CHO cells transfected with CYP1A2 and different NAT2 alleles. This advantageous 
mammalian resource mimics the human cells, providing further study of the 
individual role of NAT2 regardless of the NAT1 acetylation activity.  
Our findings clearly illustrate NAT2 genotype-dependent N-acetylation of 
ABP, BNA and MOCA in human hepatocytes and hydralazine, INH, BNA and 
MOCA in CHO cells transfected with human NAT2. These results suggest the 
individual susceptibility to side effects or toxicity of these chemicals can be 




Moreover, the results refer to the different N-acetylation rates among the 
allelic variants normally associated with slow acetylator phenotype suggesting 
NAT2 slow acetylator phenotype is not homogeneous. Instead, multiple slow 
acetylator phenotypes exist resulting from different mechanisms inferred by 
various SNPs. Therefore, the investigations of NAT2 genotype/phenotype 
relationship could be more precise and reproducible if heterogeneity within the 
“slow” NAT2 acetylator phenotype is considered and incorporated into the study 
design. 
 
WEAKNESSES AND LIMITATIONS: 
Poor availability of in human hepatocytes and restricted proliferation 
capacity in vitro hindered the study of some NAT2 genotypes as NAT2*7 which 
can affect substrate affinity. Larger sample size for the various genotypes would 
give more accurate findings. 
Use of high concentration of arylamine carcinogens led to significant loss of 
cell viability. This may explain the undetectable amount of the acetylated product 
for some carcinogens. To mitigate that, future studies should include treatment of 
cells with less carcinogen’s concentrations or incubation of carcinogen with cells 
for shorter periods (less than 24 hours). 
In the present study, we did not investigate AcCoA kinetics to detect the 
effect of different NAT2 alleles on AcCoA affinity. This would provide an 





Future studies should include investigation of genotoxic effects induced by 
aromatic carcinogens in human hepatocytes and CHO cells expressing different 
NAT2 genotypes. These effects include DNA damage, adducts, and formation of 
mutants. Also, further studies are needed to determine the mechanisms underlying 
cytotoxicity and/or genotoxicity. This could include detection of apoptotic proteins 
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ABP 4-Aminobiphenyl 
Acetyl-CoA Acetyl coenzyme A 
AF 2-Aminofluorene 
ANOVA Analysis of variance 
AαC 2-amino-9H-pyrido[2,3-b] indole  
BNA β-Naphthylamine 
CHO Chinese hamster ovary 
EDTA Ethylenediaminetetraacetic acid 
EROD Ethoxyresorufin O-deethylation 
HPLC High performance liquid chromatography 
IARC International Agency for Research on Cancer 
INH Isoniazid 




MTP 3-methyl-s-triazolo [3,4a]-phthalazine  
NAT1 Arylamine N-acetyltransferase 1 
NAT2 Arylamine N-acetyltransferase 2 
NER Nucleotide excision repair 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
PhIP  2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine 
ROS Reactive oxygen species 
SMZ Sulfamethazine 
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